Vehlo Deepens Dealership Capabilities with Acquisition of Total Customer Connect
By uniting the strengths of Vehlo and TCC, this acquisition delivers enhanced capabilities for dealership operations, providing a more unified and intelligent customer engagement experience.
The acquisition enhances Vehlo's commitment to optimizing dealership service lanes, adding TCC's service lane software solutions, advanced marketing & CRM, and retention tools into Vehlo's expanding suite of dealership solutions. TCC's platform empowers dealerships with features such as automated service reminders, digital multipoint inspection (MPI) presentations, declined service capture, personalized marketing campaigns, and robust analytics designed to drive revenue, improve retention, and elevate customer experience.
"At Vehlo, we're focused on helping service teams operate efficiently while fostering lasting customer relationships," stated Josh Weis, CEO of Vehlo. "TCC has developed cutting-edge solutions that enable dealerships to better engage with their customers throughout the service lifecycle. We're excited to welcome TCC to the Vehlo team, as their technology perfectly complements our existing ecosystem."
By uniting the strengths of Vehlo and TCC, this acquisition delivers enhanced capabilities for dealership operations, providing a more unified and intelligent customer engagement experience. The partnership aligns with Vehlo's strategic vision of delivering end-to-end workflow solutions tailored to the automotive retail and service markets, with half of all franchise dealers now relying on Vehlo-driven products to power their operations.
'Joining forces with Vehlo marks a significant milestone for TCC,' said Shawn Rajabi, CEO of Total Customer Connect. 'Together, we'll bring unparalleled value to dealerships by combining TCC's service lane software suite and marketing solutions with Vehlo's comprehensive suite of service lane and payment solutions to drive incremental revenue for our customers. This collaboration allows us to drive stronger results for our customers and expand our market influence.'
With this acquisition, TCC will retain its dealer-focused approach while leveraging Vehlo's extensive network, resources, and complementary technologies. Dealers can look forward to accelerated innovation, seamless integration across platforms, and increased support for boosting fixed operations profitability.
Presidio Technology Partners acted as the exclusive financial advisor to TCC in this transaction.
About Vehlo
Vehlo delivers integrated software and financial solutions to empower success in the vehicle service industry. From dealership service lanes to independent repair shops, Vehlo supports over 30,000 customers globally, processing more than $10 billion in annual payments. Focused on enabling efficiency, revenue growth, and superior customer experiences, Vehlo is reshaping the way automotive repair businesses operate and thrive. For more information, visit vehlo.com.
About Total Customer Connect (TCC)
Total Customer Connect provides powerful customer retention and service marketing solutions specifically designed for automotive dealerships. With advanced platforms for automating service communications, capturing declined services, and personalizing customer engagement, TCC helps dealerships boost revenue and improve loyalty while ensuring a premium service experience. Learn more at main.totalcustomerconnect.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Recursion Pharmaceuticals (RXRX) Price Surges 9% Over Past Month
Recursion Pharmaceuticals experienced a price increase of 9% over the past month, positioning it against the backdrop of a broader market decline driven by geopolitical tensions and weak jobs data. Despite these broader market headwinds, which saw significant tech stock declines due to tariff concerns and disappointing economic indicators, Recursion managed to outperform. The company's stock movement appeared isolated from these wider trends, which implies internal factors or developments might have played a part, although specific catalysts weren't highlighted during this period. This performance is noteworthy given the current market's overall downward trend of 2.7%. We've identified 3 possible red flags for Recursion Pharmaceuticals (1 is potentially serious) that you should be aware of. AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Recursion Pharmaceuticals' recent 9% monthly share price increase amidst broader market declines may suggest that internal developments, rather than external factors, are influencing investor sentiment. Over the past year, however, the company's total shareholder return was a decline of 19.09%, highlighting a contrast to the short-term positive movement. Comparatively, RXRX underperformed the US Biotechs industry, which saw an 8.4% decline over the same period, and also lagged behind the US market return of 17.7%. The heightened interest in the stock could be linked to enthusiasm around its AI-driven drug discovery programs, including REC-617 and REC-994 trials, which suggest potential future revenue growth. Yet, Recursion's lack of profitability and reliance on successful trial outcomes may introduce uncertainty into earnings forecasts. The company's expected revenue growth of 39.9% annually for the next three years could be influenced by the new developments and partnerships, possibly providing support to the optimistic forecasts. The current share price of US$5.68 remains below the consensus analyst price target of US$7.14, indicating a potential upside of 25.7%. This price target reflects expectations of significant future revenue and earnings improvements. However, analysts' forecasts include assumptions such as increased profit margins and successful translation of ongoing projects into commercial revenues, underscoring the importance of navigating the risks and uncertainties outlined in their analysis. Investors may need to weigh these factors carefully when considering the company's ability to meet future targets. Evaluate Recursion Pharmaceuticals' prospects by accessing our earnings growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include RXRX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Business Upturn
2 days ago
- Business Upturn
Search Business Group Launches Generative SEO Services in Southern California to Help Healthcare Providers Dominate AI Search
Fullerton, CA, Aug. 01, 2025 (GLOBE NEWSWIRE) — Search Business Group, a Latino-owned digital marketing agency based in Southern California, announced the launch of its new Generative Engine Optimization (GEO) services to help doctors, dentists, and veterinary practices rank on AI-driven search platforms like ChatGPT, Perplexity, and Gemini. The new offering positions providers across the region to stay visible and competitive as patient search behavior shifts toward generative AI platforms. Ron Arellano, Founder and Creative Director of Search Business Group, leads healthcare marketing innovation with a focus on inclusivity, data-driven strategy, and digital visibility. The agency's healthcare-specific strategies have led to significant performance outcomes for practices across Orange County and beyond. One example includes New Generation Dentistry in Mission Viejo, which achieved a 300% increase in year-over-year revenue, a 60% increase in local search traffic, and a 70% rise in phone leads following a comprehensive campaign involving web development, SEO, and content optimization. Search Business Group is led by award-winning Creative Director Ron Arellano, whose background includes more than two decades of creative leadership across high-profile brands such as the NY Mets, T-Mobile, Bridgestone, and WeightWatchers. Under Arellano's direction, the agency has pivoted its expertise toward the healthcare sector, bringing global-level strategy to small and mid-sized practices. 'Doctors and specialists often lack access to custom marketing that reflects their unique voice and community,' said Arellano. 'Search Business Group fills that gap with culturally aware campaigns that produce real business results.' The agency has supported a wide range of providers—including orthodontists, oral surgeons, veterinary clinics, and med spas—by combining human-centered design with technical precision. Its approach emphasizes performance analytics, local SEO, and user-first content while also addressing representation and language equity in healthcare communications. As part of its forward-looking strategy, Search Business Group has also introduced Generative Engine Optimization (GEO) services to help healthcare providers rank in AI-driven search engines such as ChatGPT, Perplexity, and Gemini. This positions clients to stay visible and competitive as consumer search behavior continues to evolve. Search Business Group's foundation is rooted in both innovation and inclusion. As a first-generation immigrant from Ecuador, Arellano brings a cultural fluency that informs the agency's work across diverse markets. Search Business Group continues to expand its reach while prioritizing equity, trust, and growth in healthcare marketing. About Search Business Group Search Business Group is a Fullerton, California-based digital marketing agency specializing in healthcare, dental, and veterinary marketing. The Latino-owned firm offers services in SEO, web design, web development, content strategy, and generative search optimization, helping healthcare providers improve digital visibility and patient engagement through performance-driven, culturally informed solutions. Real Results: A 528% increase in online patient forms from January to July 2025, generating over $1.4 million in estimated revenue through digital strategy and local SEO. Press inquiries Search Business Group Bianca Montalvo [email protected] 714-519-6290 1316 North Placentia Ave. Fullerton, CA 92831
Business Upturn
3 days ago
- Business Upturn
Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds
Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) ('Silexion Therapeutics' or the 'Company'), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 152,106 of the Company's ordinary shares originally issued in January 2025 at a reduced exercise price of $11.57 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-282932) and an effective resale registration statement on Form S-1 (No. 333-284873). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1.8 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase up to 304,212 of the Company's ordinary shares. The new warrants will have an exercise price of $11.32 per share, will be exercisable upon the effective date of the increase of the Company's authorized ordinary shares following shareholder approval and will have a term of twenty-four months from the effective date of the Resale Registration Statement (as defined below). The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the '1933 Act') and, along with the ordinary shares issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ('SEC') or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the ordinary shares issuable upon exercise of the new warrants (the 'Resale Registration Statement'). This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Silexion Therapeutics Silexion Therapeutics Corp is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The Company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: Notice Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from the offering. These forward-looking statements are generally identified by terminology such as 'may', 'should', 'could', 'might', 'plan', 'possible', 'project', 'strive', 'budget', 'forecast', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. For example, the Company is using forward-looking statements when it discusses the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) whether Silexion is able to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) whether Silexion succeeds at maintaining the listing of its securities on the Nasdaq Capital Market. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law. Company Contact: Silexion Therapeutics CorpMs. Mirit Horenshtein Hadar, CFO [email protected]
